Risankizumab Significantly Reduces, Resolves Symptoms of Crohn Disease
Patients with Crohn disease (CD) reported an improvement in symptoms with the induction of risankizumab to their management treatment, according to a study presented at The American College of Gastroenterology 2022 Annual Scientific Meeting in Charlotte, NC.
CD causes symptoms that are burdensome and dilapidating for patients such as abdominal pain and increased stool frequency. Clinicians and their patients aim to resolve these symptoms as soon as they can. The researchers examined the patient reported outcomes in abdominal pain and stool frequency, looking at the correlation with endoscopic outcomes.
Using pooled data from the ADVANCE/MOTIVATE induction studies and the FORTIFY maintenance study, the researchers looked at the clinical outcomes for abdominal pain and stool frequency. During the study, participants recorded their CD-related symptoms daily in an electronic diary that was reviewed during each study visit. The participants gave the abdominal pain a rating from 0 (none) to 3 (severe).
Overall, patients reported an improvement in symptoms when risankizumab induction therapy was introduced, with a dose of 360 mg as the most effective in resolving symptoms when compared to participants who received a placebo.
“Symptom improvements and endoscopic outcomes were moderately correlated,underscoring the importance of an objective measure to assess disease activity,” the researchers concluded.
Louis E, Torres J, Lindsay J, et al. Induction and maintenance treatment with Risankizumab leads to symptomatic relief in patients with moderate to severe Crohn’s disease. Presented at The American College of Gastroenterology 2022 Annual Scientific Meeting in Charlotte, NC; October 21-26; Charlotte, NC. Accessed October 19, 2022.